Information for COVID-19 Therapeutics Providers

Texas Case Counts microscopic example of a coronavirus

This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact or call Provider Support at 833‑832‑7068, option 0.

On this page:

News & Updates

Bebtelovimab No Longer Authorized as of 11/30/22

Bebtelovimab is no longer authorized by the FDA for use in the United States, effective immediately. See the 11/30/22 DSHS letter to therapeutics providers for complete details.

Weekly eDigests (PDFs)

How to Become a COVID-19 Therapeutics Provider

To enroll as a therapeutics provider, please email or call Provider Support at 833‑832‑7068, option 0.

Therapeutics Products

Click on any of the buttons below to access a list of product-specific resources.

Shelf-life extension information can be found individually in each of the applicable product-specific sections, as well as in the Shelf-Life Extensions section below.

For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.

Monoclonal Antibody (mAb) Products

Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline) Bebtelovimab (Lilly)

Long-Acting Antibody (LAAB) Product

Evusheld: tixagevimab + cilgavimab (AstraZeneca)

Oral Antiviral Products

Lagevrio (molnupiravir) (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)

Shelf-Life Extensions

Texas COVID-19 Product Availability

Job Aids & FAQs


Billing & Coding Information

▲ Top

This page is being updated as new information becomes available.

Last updated December 5, 2022